Loading…
Loading…
BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
On October 21, 2026, DexCom Inc (DXCM) shares fell 6.4% to a current price of $80.26. This decline comes amidst a 52-week range of $54.11 to $92.59, highlightin
DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
DexCom, Inc. (NASDAQ: DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the sale, the executive vice president directly owned 98,185 shares in
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut manufacturing costs, driving Q2 2026 gross margin up 400 bps to 64.1% and enabling 70% incremental operating margins. CONNECT study results published in NEJM reinforce DXCM's clinical leadership, particularly among GLP-1 users, supporting expanded coverage and future growth.
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pill in ulcerative colitis, and a discovery about ovaries after menopause.